.Cambridge Healthtech Institute’s #DrugDiscoveryChemistry conference begins today & our own Dan Sherman, Principal Research Investigator, will share a brief presentation on our pipeline and platform work. Full agenda here: bit.ly/3aPsJTg #drugdevelopment #TPD

I’m still amazed by the impact this 20 year old paper had on launching the #TPD field. Looking forward to all of the exciting innovation to come in the next two decades! #PROTACs

Love this!!! Be a brave person and create an environment not of fear and intimidation but one that welcomes innovation. Don’t settle- challenge conventional wisdom in a way that fosters innovation and risk taking. www-forbes-com.cdn.ampproject.org/c/s/www.forbes…

Gladstone Neuroscience Researcher Elected to the National Academy of Medicine | BioSpace biospace.com/article/releas…

PROTAC targeted protein degraders: the past is prologue go.nature.com/3rwBUQb - a new review by Miklos Bekes and David Langley Arvinas and Craig Crews covering the status of clinical translation of targeted protein degradation and key areas for the future of the field

Celebration of John Trowjanowski, MD, PhD and his incredible contributions and dedication to our understanding of Neurodegeneration and pathology of these diseases m.youtube.com/watch?v=l2PDB9…

At #Arvinas, we believe we must encourage next gen researchers in order to see growth w/ in our respective fields. I’m proud to introduce Arvinas’ Early Career Researcher Award, dedicated to those breaking new ground in #TPD. Read more & share️⬇️#Arvinas linkedin.com/pulse/investin…

Please join me for the 5th Annual TPD summit October 25-28th, 2022 in Boston. #TPD #Arvinas proteindegradation.com

📣 📣 Exactly 1 wk left to submit applications for the #Arvinas Early Career Researcher Award, which will be announced at The UnDruggable Series 5th Annual Targeted Protein Degradation Summit in October! Get the award details here: bit.ly/ArvinasECRA #AECRA22 #TPD

Last call TPD community for nominations!!! #https://www.linkedin.com/feed/update/urn:li:activity:6957318658696060928?updateEntityUrn=urn%3Ali%3Afs_feedUpdate%3A%28V2%2Curn%3Ali%3Aactivity%3A6957318658696060928%29

Congratulations to Dr. Katherine Donovan Katherine A Donovan on receiving the Arvinas Early Career Researcher Award! We are all very proud of you! #TPD

Important CNS biomarker work to understand fAD disease progression! nature.com/articles/s4159…

Ava Valianti - bubble wrap lefuturewave.com/2023/10/20/ava… #talent #songwriter

facebook.com/story.php?stor…

Strong data set disclosed by Steven Sparks Arvinas at #TPD23 showing degradation of brain #LRRK2 by an orally dosed #PROTAC in non-human primates. Another frontier in the #TPD space about to be overcome! Disease-causing proteins in neurological diseases now in scope!

Our first in-person gathering!!! What a tremendous group.

#NEWS: With @Pfizer, we’re pleased to announce positive topline progression-free survival results from a Phase 3 clinical trial in adults with ER+/HER2- advanced or metastatic #BreastCancer in patients whose tumors harbor ESR1 mutations. Learn how these results may help us

At Arvinas, we're proud to advance groundbreaking science that aim to reshape the treatment of neurological diseases. By harnessing #ScienceOfPROTAC, we're targeting disease-causing proteins previously considered "undruggable," and potentially unlocking new therapeutic

#NEWS:Arvinas Presents First-in-Human Data for Investigational Oral novel PROTAC LRRK2 Degrader Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation. Read More: bit.ly/4hXSctC